NCT06027957 is a Phase 1 clinical trial of anti-CD19 CAR T-cells in B-Cell Non Hodgkin Lymphoma, sponsored by Vinmec Research Institute of Stem Cell and Gene Technology.

Who is sponsoring NCT06027957?

NCT06027957 is sponsored by Vinmec Research Institute of Stem Cell and Gene Technology.

What drugs are being tested in NCT06027957?

Interventions in NCT06027957: anti-CD19 CAR T-cells.

What condition does NCT06027957 study?

NCT06027957 studies B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia.

Is NCT06027957 still recruiting?

NCT06027957 is currently completed. Last updated 26 August 2025.

Last reviewed 2025-08-26 · How we verify

NCT06027957

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia

Completed Phase 1 Last updated 26 August 2025

What this trial tests

Phase 1 trial testing anti-CD19 CAR T-cells in B-Cell Non Hodgkin Lymphoma in 18 participants. Completed in 31 July 2025.

Timeline

2 August 2023

Primary endpoint
30 June 2025

31 July 2025

Quick facts

Lead sponsor	Vinmec Research Institute of Stem Cell and Gene Technology
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	2 August 2023
Primary completion	30 June 2025
Estimated completion	31 July 2025
Sites	1 location across Vietnam

Drugs / interventions tested

anti-CD19 CAR T-cells — full drug profile →

Conditions studied

B-Cell Non Hodgkin Lymphoma — all drugs for B-Cell Non Hodgkin Lymphoma →
B-Cell Acute Lymphoblastic Leukemia — all drugs for B-Cell Acute Lymphoblastic Leukemia →

Sponsor

Vinmec Research Institute of Stem Cell and Gene Technology

Who can join

Adults 1 to 60, any sex, with B-Cell Non Hodgkin Lymphoma or B-Cell Acute Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

* Brief Summary: Cluster of differentiation 19 (CD19) is expressed on B cells. CD19+ tumor cells in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia can be targeted using T cells expressing CD19-specific chimeric antigen receptor (CAR). * Objective: This study aims to evaluate the safety and efficacy of single-dose anti-CD19 CAR T-cell therapy in the treatment of relapsed/refractory CD19+ non-Hodgkin lymphoma and acute lymphoblastic leukemia. * Eligibility: People aged 1 to 60 years with relapsed/refractory CD19+ non-Hodgkin lymphoma and acute lymphoblastic leukemia. * Design: Phase 1 clinical trial, uncontrolled, single dose of CD19 CAR T-cells.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma.
Ostojska M, Nowak E, Twardowska J, Lejman M, et al · · 2023 · cited 5× · PMID 38003910 · DOI 10.3390/jpm13111595
Outcomes of point-of-care manufactured CAR T cell therapy for B cell acute lymphoblastic leukemia and non-Hodgkin lymphoma in Vietnam.
Nguyen LT, Nguyen DD, Bach QK, Dao LTM, et al · · 2026 · PMID 41809369 · DOI 10.1016/j.omton.2026.201156

Verify or expand the search:

Other Vinmec Research Institute of Stem Cell and Gene Technology trials

Trials by the same sponsor.

NCT07472270 — Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment · Phase 1 · not yet recruiting
NCT06629324 — Evaluating Bone Marrow Cell Transplant for Treating Cerebral Palsy From Brain Hypoxia · Phase 2 · recruiting
NCT06726538 — Investigating the Efficacy of Autologous, Adipose-derived Mesenchymal Stem Cell Therapy for the Treatment of Sexual Func · Phase 1, PHASE2 · completed
NCT05329662 — Adipose Tissue-derived Mesenchymal Stem Cell (AD-MSC) Therapy for the Treatment of Sexual Function Impairment in Female · Phase 2 · recruiting
NCT05345418 — Umbilical Cord-Derived Mesenchymal Stem Cell (VCELL 1) for Male Patients With Sexual Deficiency · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06027957 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vinmec Research Institute of Stem Cell and Gene Technology
Last refreshed: 26 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06027957.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing